1. B. M. Gumbiner, Epithelial morphogenesis. Cell 69, 385–387 (1992).
2. R. Kalluri, E. G. Neilson, Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776–1784 (2003).
3. J. P. Their, Epithelial-mesenchymal transitions in tumor progression. Nat. Rev. Cancer 2, 442–454 (2002).
4. M. A. Nieto, R. Y. Y. J. Huang, R. A. A. Jackson, J. P. P. Thiery, EMT: 2016. Cell 166, 21–45 (2016).
5. C. Yeaman, K. K. Grindstaff, M. D. H. Hansen, W. J. Nelson, Cell polarity: Versatile scaffolds keep things in place. Curr. Biol. 9, R515–R517 (1999).
6. M. P. Stemmler, R. L. Eccles, S. Brabletz, T. Brabletz, Non-redundant functions of EMT transcription factors. Nat. Cell Biol. 21, 102–112 (2019).
7. J. Yang, et al., Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020).
8. A. M. Krebs, et al., The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529 (2017).
9. T. Shibue, R. A. Weinberg, EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).
10. I. Pastushenko, et al., Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018).
11. E. Romeo, C. A. Caserta, C. Rumio, F. Marcucci, The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System. Cells 8, 460 (2019).
12. W. Lu, Y. Kang, Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. Dev. Cell 49, 361–374 (2019).
13. P. B. Gupta, I. Pastushenko, A. Skibinski, C. Blanpain, C. Kuperwasser, Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. Cell Stem Cell 24, 65–78 (2019).
14. M. Binnewies, et al., Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
15. T. L. Whiteside, The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904–5912 (2008).
16. Y. K. Chae, et al., Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci. Rep. 8, 1–8 (2018).
17. N. M. Aiello, et al., EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration Developmental Cell Article EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev. Cell 45, 681–695 (2018).
18. R. Kalluri, The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
19. A. W. Lambert, D. R. Pattabiraman, R. A. Weinberg, Emerging Biological Principles of Metastasis. Cell 168, 670–691 (2017).
20. P. Sharma, J. P. Allison, The future of immune checkpoint therapy. Science (80-. ). 348, 56–61 (2015).
21. V. Koliaraki, A. Prados, M. Armaka, G. Kollias, The mesenchymal context in inflammation, immunity and cancer. Nat. Immunol. 21, 974–982 (2020).
22. J. Galon, D. Bruni, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
23. N. Nagarsheth, M. S. Wicha, W. Zou, Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559–572 (2017).
24. R. H. Vonderheide, The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33, 563–569 (2018).
25. C. Grasselly, et al., The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent. Front. Immunol. 9, 1–13 (2018).
26. S. I. S. Mosely, et al., Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol. Res. 5, 29–41 (2017).
27. A. Amedei, E. Niccolai, D. Prisco, Human Vaccines & Immunotherapeutics Pancreatic cancer: Role of the immune system in cancer progression and vaccine- based immunotherapy Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. 10, 3354–3368 (2014).
28. L. L. van der Woude, M. A. J. Gorris, A. Halilovic, C. G. Figdor, I. J. M. de Vries, Migrating into the Tumor: a Roadmap for T Cells. Trends in Cancer 3, 797–808 (2017).
29. W. Zheng, et al., Combination of radiotherapy and vaccination overcome checkpoint blockade resistance. Oncotarget 7, 43039–43051 (2016).
30. J. Galon, D. Bruni, Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity 52, 55–81 (2020).
31. C. E. Clark, et al., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518–9527 (2007).
32. D. I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
33. J. Roelands, et al., Immunogenomic classification of colorectal cancer and therapeutic implications. Int. J. Mol. Sci. 18, 2229 (2017).
34. A. B. Blair, et al., IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J. Clin. Invest. 129, 1742–1755 (2019).
35. P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707–723 (2017).
36. X. Xu, L. Ye, K. Araki, R. Ahmed, MTOR, linking metabolism and immunity. Semin. Immunol. 24, 429–435 (2012).
37. R. J. Deberardinis, N. S. Chandel, Fundamentals of cancer metabolism INTRODUCTION AND OVERARCHING PRINCIPLES. Sci. Adv. 2, 1–18 (2016).
38. E. Menares, et al., Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat. Commun. 10, 4401 (2019).
39. J. D. Mezrich, et al., An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J. Immunol. 185, 3190–3198 (2010).
40. D. H. Munn, A. L. Mellor, IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. 37, 193–207 (2016).
41. A. L. Mellor, D. H. Munn, Tryptophan Catabolism and Regulation of Adaptive Immunity. J. Immunol. 170, 5809–5813 (2003).
42. J. E. Cheong, L. Sun, Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities. Trends Pharmacol. Sci. 39, 307–325 (2018).
43. J. Godin-Ethier, L. A. Hanafi, C. A. Piccirillo, R. Lapointe, Indoleamine 2,3- dioxygenase expression in human cancers: Clinical and immunologic perspectives. Clin. Cancer Res. 17, 6985–6991 (2011).
44. M. Liu, et al., Targeting the IDO1 pathway in cancer: From bench to bedside. J. Hematol. Oncol. 11, 1–12 (2018).
45. O. Takikawa, A. Habara-Ohkubo, R. Yoshida, IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J. Immunol. 145, 1246–1250 (1990).
46. W.-P. M. Urquhart, et al., RNA Interference Immunosuppressive Molecule IDO through Inhibiting Tumor-Derived Reinstalling Antitumor Immunity by. J. Immunol. 177, 5639–5646 (2006).
47. L. Zhai, et al., IDO1 in cancer: a Gemini of immune checkpoints. Cell. Mol. Immunol. 15, 447–457 (2018).
48. C. Uyttenhove, et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
49. S. L. Deshmane, S. Kremlev, S. Amini, B. E. Sawaya, Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interf. Cytokine Res. 29, 313–325 (2009).
50. M. C. Miller, K. H. Mayo, Molecular Sciences Chemokines from a Structural Perspective. Int. J. Mol. Sci. 18, 2088 (2017).
51. T. Yoshimura, The chemokine MCP-1 (CCL2) in the host interaction with cancer: A foe or ally? Cell. Mol. Immunol. 15, 335–345 (2018).
52. B. H. Li, M. A. Garstka, Z. F. Li, Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol. Immunol. 117, 201–215 (2020).
53. D. Wilsker, et al., Nomenclature of the ARID family of DNA-binding proteins. Genomics 86, 242–251 (2005).
54. B. Zheng, H. He, Y. Zheng, W. Wu, S. McCormick, An ARID Domain-Containing Protein within Nuclear Bodies Is Required for Sperm Cell Formation in Arabidopsis thaliana. PLoS Genet. 10, 1004421 (2014).
55. J. Iwahara, R. T. Clubb, Solution structure of the DNA binding domain from Dead ringer, a sequence-specific AT-rich interaction domain (ARID). EMBO J. 18, 6084–6094 (1999).
56. R. D. Kortschak, P. W. Tucker, R. Saint, ARID proteins come in from the desert. Trends Biochem. Sci. 25, 294–299 (2000).
57. S. Kang, T. Tanaka, M. Narazaki, T. Kishimoto, Targeting Interleukin-6 Signaling in Clinic. Immunity 50, 1007–1023 (2019).
58. K. Masuda, et al., Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci U S A 110, 9409–9414 (2013).
59. J. P. Chalise, et al., Feedback regulation of Arid5a and Ppar-γ2 maintains adipose tissue homeostasis. Proc. Natl. Acad. Sci. U. S. A. 116, 15128–15133 (2019).
60. K. K. Nyati, R. G. Agarwal, P. Sharma, T. Kishimoto, Arid5a Regulation and the Roles of Arid5a in the Inflammatory Response and Disease. Front. Immunol. 10, 2790 (2019).
61. T. Tanaka, M. Narazaki, T. Kishimoto, IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).
62. Y. Lou, et al., Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22, 3630–3642 (2016).
63. A. Dongre, R. A. Weinberg, New insights into the mechanisms of epithelial– mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69– 84 (2019).
64. X. Zheng, et al., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).
65. R. L. Porter, et al., Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 116, 26835–26845 (2019).
66. P. Bailey, et al., Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
67. M. B. Wachsmann, L. M. Pop, E. S. Vitetta, Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J. Investig. Med. 60, 643–63 (2012).
68. E. P. Kopantzev, et al., Activation of IGF/IGF-IR signaling pathway fails to induce epithelial-mesenchymal transition in pancreatic cancer cells. Pancreatology 19, 390– 396 (2019).
69. A. V. Biankin, et al., Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
70. R. H. Hruban, et al., An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. Am. J. Surg. Pathol. 28, 977–987 (2004).
71. N. Waddell, et al., Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
72. S. R. Hingorani, et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).
73. M. K. Wendt, T. M. Allington, W. P. Schiemann, Mechanisms of the epithelial- mesenchymal transition by TGF-β. Futur. Oncol. 5, 1145–1168 (2009).
74. J. Xu, S. Lamouille, R. Derynck, TGF-Β-induced epithelial to mesenchymal transition. Cell Res. 19, 156–172 (2009).
75. C. J. David, J. Massagué, Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419–435 (2018).
76. D. E. Johnson, R. A. O’Keefe, J. R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).
77. T. F. Gajewski, H. Schreiber, Y.-X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
78. C. V. Ramana, M. P. Gil, R. D. Schreiber, G. R. Stark, Stat1-dependent and - independent pathways in IFN-γ-dependent signaling. Trends Immunol. 23, 96–101 (2002).
79. D. E. Sanford, et al., Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 19, 3404–3415 (2013).
80. J. Guinney, et al., The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
81. A. E. Yuzhalin, et al., Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases. Am. J. Physiol. - Gastrointest. Liver Physiol. 317, G625-E639 (2019).
82. B. Zhang, et al., Antimetastatic Role of Smad4 Signaling in Colorectal Cancer. Gastroenterology 138, 969–980 (2010).
83. S. Mariathasan, et al., TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
84. J. Zhu, H. Yamane, W. E. Paul, Differentiation of effector CD4+ T cell populations. Annu. Rev. Immunol. 28, 445–489 (2010).
85. E. J. Wherry, et al., Lineage relationship and protective immunity of memory CD8T cell subsets. Nat. Immunol. 4, 225–234 (2003).
86. T. Phan, et al., Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Ther. 27, 235–245 (2020).
87. J. Li, et al., Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49, 178–193 (2018).
88. D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1–10 (2013).
89. P. S. Hegde, D. S. Chen, Perspective Top 10 Challenges in Cancer Immunotherapy. Immunity 52, 17–35 (2020).
90. S. Lamouille, J. Xu, R. Derynck, Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
91. N. J. Sullivan, et al., Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940–2947 (2009).
92. A. Yadav, B. Kumar, J. Datta, T. N. Teknos, P. Kumar, IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3- SNAIL signaling pathway. Mol. Cancer Res. 9, 1658–1667 (2011).
93. D. Bruni, H. K. Angell, J. Galon, The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).
94. A. J. Muller, M. G. Manfredi, Y. Zakharia, G. C. Prendergast, Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin. Immunopathol. 41, 41–48 (2019).
95. T. C. Mitchell, et al., Epacadostat plus pembrolizumab in patients with advanced solid tumors: Phase I results from a multicenter, open-label phase I/II trial (ECHO- 202/KEYNOTE-037). J. Clin. Oncol. 36, 3223–3230 (2018).
96. T. M. Nywening, et al., Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651–662 (2016).
97. A. Kalbasi, et al., Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 23, 137–148 (2017).
98. W. Bin Fang, et al., CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J. Biol. Chem. 287, 36593–36608 (2012).
99. J. Galon, W. H. Fridman, F. Pages, The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res. 67, 1883–1886 (2007).
100. S. R. Hingorani, et al., Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).
101. S. Hashimoto, et al., ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 116, 17450–17459 (2019).
102. H. E. Mei, M. D. Leipold, H. T. Maecker, Platinum-conjugated antibodies for application in mass cytometry. Cytom. Part A 89, 292–300 (2016).
103. F. J. Hartmann, E. F. Simonds, S. C. Bendall, A Universal Live Cell Barcoding- Platform for Multiplexed Human Single Cell Analysis. Sci. Rep. 8, 10770 (2018).
104. M. H. Spitzer, et al., An interactive reference framework for modeling a dynamic immune system. Science (80-. ). 349, 1259425–1259425 (2015).
105. N. Samusik, Z. Good, M. H. Spitzer, K. L. Davis, G. P. Nolan, Automated mapping of phenotype space with single-cell data. Nat. Methods 13, 493–496 (2016).
論文の公開元へ
